Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Share-based Compensation (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Share-based Compensation data on record, last reported at $6.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 10.17% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $27.3 million, up 11.94%, while the annual FY2025 figure was $27.3 million, 11.94% up from the prior year.
  • Share-based Compensation reached $6.2 million in Q4 2025 per AMPH's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.4 million in Q1 2025 and bottomed at $3.8 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $5.4 million, with a median of $5.3 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: crashed 40.32% in 2021, then rose 21.85% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2021, then increased by 11.79% to $4.3 million in 2022, then increased by 7.39% to $4.6 million in 2023, then increased by 21.85% to $5.6 million in 2024, then grew by 10.17% to $6.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $6.2 million in Q4 2025, $6.3 million in Q3 2025, and $6.4 million in Q2 2025.